𝔖 Bobbio Scriptorium
✦   LIBER   ✦

An Epidermal Growth Factor Receptor Promoter Construct Selectively Expresses in the Thymus and Spleen of Transgenic Mice

✍ Scribed by Chamelli Jhappan; Cheryl Stahle; Michael Wolff; Glenn Merlino; Ira Pastan

Book ID
112238665
Publisher
Elsevier Science
Year
1993
Tongue
English
Weight
345 KB
Volume
149
Category
Article
ISSN
0008-8749

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Altered expression of epidermal growth f
Altered expression of epidermal growth factor receptor ligands in tumor promoter–treated mouse epidermis and in primary mouse skin tumors induced by an initiation-promotion protocol
✍ Kaoru Kiguchi; Linda Beltrán; Tim Rupp; John DiGiovanni 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 734 KB

Multiple epidermal growth factor receptor (EGFr) ligands have been identified, including transforming growth factor α (TGFα), heparin-binding epidermal growth factor (HB-EGF), amphiregulin (AR), and betacellulin (BTC). Previous work from our laboratory demonstrated that TGFα mRNA and protein are upr

Sensory epithelium of the vomeronasal or
Sensory epithelium of the vomeronasal organ express TrkA-like and epidermal growth factor receptor in adulthood: An immunohistochemical study in the horse
✍ Garcia-Suarez, O. ;Germanà, G. ;Naves, F.J. ;Ciriaco, E. ;Represa, J. ;Vega, J.A 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 915 KB

## Background: The medial wall of the vomeronasal organ (VNO) is lined with a sensory epithelium that is closely related to the olfactory epithelium, which is developed from the olfactory placode. It undergoes continuous replacement during its life span. In other sensory epithelia, cell proliferat

Antitumor activity of the selective epid
Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa® (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo
✍ Ichiro Naruse; Tohru Ohmori; Yoko Ao; Hisao Fukumoto; Toshio Kuroki; Masatomo Mo 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 216 KB 👁 1 views

## Abstract Selective tyrosine kinase inhibitors are regarded as promising antitumor agents for cancer treatment. Iressa® (ZD1839) is an orally active, selective EGFR‐TKI (epidermal growth factor receptor‐tyrosine kinase inhibitor) that blocks signal transduction pathways implicated in cancer cell